Chief Healthcare Executive October 22, 2024
Ron Southwick

Robert Califf talked about the difficulties in regulating AI technologies, why he fears AI could exacerbate inequities, and the need for a better supply chain.

Las Vegas – With the growth of artificial intelligence and other technologies evolving so rapidly, Robert Califf says the Food and Drug Administration is going to have to change as well.

The FDA commissioner outlined the challenge during a 20-minute conversation at the HLTH conference Monday.

“We’re entering an era where we’re going to have to rethink everything we do because of the technology changes that we’re seeing, which affect every single industry that we’re dealing with,” Califf said.

The FDA is dealing with the difficulties of the rapid growth in AI technology. As Califf...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Conferences / Podcast, FDA, Govt Agencies, Trends
FDA warns GLP-1 compounder over safety rules
GLP-1 drug approvals: A breakdown
Rethinking FDA’s Accelerated Approval Pathway: New Draft Guidances and Implications for Drug Companies
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
Certainty vs. speed: How do patients feel about the tradeoff for new cancer drugs?

Share This Article